Beilai Bio biopharmaceutical company focusing on the development of stem cell therapeutics for different diseases
Beilai Bio has raised $47.1M in total funding. The most recent round was Series B. The last funding was announced in April 2022.
Beilai Bio's investors include DT Capital Partners, SDIC Venture Capital, Huajin Capital, Nanjing Jiangbei New Area Industrial Investment Group.
Beilai Bio is headquartered in Irvine, United States.
Beilai Bio biopharmaceutical company focusing on the development of stem cell therapeutics for different diseases
Beilai Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Beilai Bio — Funding & Investors." VCBacked, April 15, 2022, https://www.vcbacked.co/company/beilai-bio. Accessed September 30, 2026.
VCBacked. (2022). Beilai Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/beilai-bio
{{cite web |title=Beilai Bio — Funding & Investors |url=https://www.vcbacked.co/company/beilai-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated